% | $
Quotes you view appear here for quick access.

InVivo Therapeutics Holdings Corp. Message Board

  • a1ag a1ag Jan 15, 2013 10:47 AM Flag

    NVIV Is Not Using 3D Printing

    NVIV is NOT doing 3D printing. I have noticed a number of reports saying planning etc.. but they did kept it simple. Thank goodness! 3D would of been a challange and very expensive. They have a Mold that they use and this is much easier for The FDA blessing. 3D is cool and new.. but cool and new is not good for FDA. The same process they used for the Monkeys they will use in the Human Trial when FDA gives the green light. I was a bit scared of 3D so I am very happy the same process that has already been used is going to be used moving forward. Ready for a nice run! The stock is still around public offering price so plenty of room to go.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • thanks for the update a1ag

      Sentiment: Strong Buy

    • According to this article from last fall and the fact they received a two million dollar loan that they said would go towards the purchase of the printers I want to know your source that says they won't be using them. It would be a huge change of plans that I can't believe would be done without a very serious reason.

      "Sep.3, 2012

      Spinal cord injuries (SCI) is an insult to the spinal cord caused from motor vehicle accidents, falls, sports injuries etc and can result in a change in its normal motor, sensory, or autonomic function.

      Currently, there are no effective treatment for SCI patients to fully restore its function.

      Cambridge, MA based InVivo Therapeutics is developing a new paradigm of care to SCI. InVivo intends to create biocompatible polymer scaffold to support a damaged spinal cord in order to stop tissue from scarring after injury.

      By minimizing these secondary injury processes, and by supporting subsequent repair and recovery, the body can locally reorganize toward functional recovery through the spared healthy tissue. This process, known as neuroplasticity, may result in partial functional recovery.

      The porous biopolymer scaffold is built from polylactic-co-glycolic acid (PLGA) and polylysine. PLGA degrades naturally inside the body without the need to remove it and it is approved by the FDA for applications like tissue engineering.

      Invivo plans to set up 46 3D printers and batch processes at their new plant in Cambridge to create the scaffolds. They are still in the process of evaluating how to manufacture the scaffolds, but the company hopes to begin clinical trials in the next year.

      "Our technology is a true platform that can be leveraged to create many products, including treatments for peripheral nerve injury and other conditions. We're currently under review at FDA for our first spinal cord injury treatment, and we look forward to receiving approval to begin those human studies," said Frank Reynolds, CEO of Invivo."

      Sentiment: Buy

      • 1 Reply to rx7171
      • Not using 3D is a really good thing. I am long NVIV and I am giving you positive information about it. Not using 3D lets them use the same technology they already used in the Monkey Trial. Your quote is from a Plastic or 3D type magazine pumping 3D printing that is very expensive. Franks Quote at the bottom does not say 3D. They took info from an old quote and merged it. PLGA is used in the body already and its not done with 3D printers so keeping the same and not re-inventing the wheel is a huge plus for NVIV. Look at StemCellinc. and Geron they tried to be to far out front and ran out of money. NVIV is taking an approved PLGA and using it in spine. This PLGA dissolves in a few weeks and it is very easy to custom cut.. like they show in the video. 3d does custom print but the simple cut is all the customizing the product needs.

        Sentiment: Strong Buy

4.50-0.20(-4.26%)Oct 25 4:00 PMEDT